HHS Announces Contract to Fund Development of Ebola Drug

BARDA will provide funding and access to subject-matter expertise and technical support toward the goal of FDA approval for ZMapp, an experimental medication.

The U.S. Department of Health and Human Services announced that its Office of the Assistant Secretary for Preparedness and Response has entered into a contract to support the development of a drug to treat Ebola patients. The $24.9 million, 18-month contract with Mapp Biopharmaceutical Inc., of San Diego, Calif., can be extended to a total of $42.3 million, according to the Sept. 2 news release.

ASPR's Biomedical Advanced Research and Development Authority will provide funding and access to subject-matter expertise and technical support for manufacturing, regulatory, and non-clinical activities. Work under the contract supports the development and manufacturing of an experimental medication named ZMapp toward the goal of U.S. Food and Drug Administration approval.

"While ZMapp has received a lot of attention, it is one of several treatments under development for Ebola, and we still have very limited data on its safety and efficacy," said Dr. Nicole Lurie, assistant secretary for preparedness and response. "Developing drugs and vaccines to protect against Ebola as a biological threat has been a long-term goal of the U.S. government, and today's agreement represents an important step forward."

Mapp Biopharmaceutical will manufacture a small amount of the drug for early-stage clinical safety studies and nonclinical studies needed to demonstrate ZMapp's safety and efficacy in people, and the company will work with BARDA on the manufacturing process, increasing production yields, and the scale of manufacturing.

Download Center

  • EHS Buyer's Guide

    Download this buyer's guide to make more informed decisions as you're looking for an EHS management software system for your organization.

  • Online Safety Training Buyer's Guide

    Use this handy buyer's guide to learn the basics of selecting online safety training and how to use it at your workplace.

  • COVID Return-to-Work Checklist, Fall 2021

    Use this checklist as an aid to help your organization return to work during the COVID-19 pandemic in a safe and healthy manner.

  • SDS Buyer's Guide

    Learn to make informed decisions while searching for SDS Management Software.

  • Risk Matrix Guide

    Risk matrices come in many different shapes and sizes. Understanding the components of a risk matrix will allow you and your organization to manage risk effectively.

  • Industry Safe

Featured Whitepapers

OH&S Digital Edition

  • OHS Magazine Digital Edition - September 2021

    September 2021

    Featuring:

    • COMBUSTIBLE DUST
      Managing Combustible Dust and Risk Mitigation
    • PPE: CONSTRUCTION
      The Rising Popularity of Safety Helmets on the Jobsite
    • PPE: ELECTRICAL SAFETY
      Five Tips for a Successful Wear Trial
    • SAFETY & HEALTH
      Medical Surveillance Versus Medical Screening
    View This Issue